Blue Cone Monochromatism (BCM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Blue cone monochromatism (BCM) is a rare X-linked congenital cone dysfunction syndrome, caused by mutations in the OPN1LW/OPN1MW gene cluster on the X chromosome. The cluster contains a single OPN1LW and one or more copies of the OPN1MW gene and controls the expression of the red (L, long wavelength) and green (M, middle wavelength) cone photoreceptor opsins. The genes expressing the opsin for the third cone subtype, S (short-wavelength) or blue cones (OPN1SW), and the rod pigment are autosomal and not affected in BCM. Consequently, vision in affected males is subserved only by S cone and rod function, as no functional L or M cones are present in the retina while Tritan discrimination, which has been reported to deteriorate with increasing illuminance and scotopic perception are retained.

·       The prevalence of Blue cone monochromatism (BCM) varies between 1 to 1.75 cases per 100,000 population. Colour discrimination is severely impaired from birth and BCM patients typically present reduced visual acuity (6/24 to 6/60), pendular nystagmus, photophobia, and often have a myopic pattern.

 

Thelansis’s “Blue Cone Monochromatism (BCM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Blue Cone Monochromatism (BCM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Blue Cone Monochromatism (BCM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Blue Cone Monochromatism (BCM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Blue Cone Monochromatism (BCM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Blue Cone Monochromatism (BCM), Blue Cone Monochromatism (BCM) market outlook, Blue Cone Monochromatism (BCM) competitive landscape, Blue Cone Monochromatism (BCM) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)